Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

WuXi Bio Partners with Medigene to Design T Cell Engagers

publication date: Aug 8, 2024

WuXi Biologics partnered with Medigene AG, a Munich Biotech, to design T cell receptor-guided T Cell Engagers (TCR-TCEs) aimed at difficult-to-treat tumors. The three-year effort will combine Medigen’s TCR expertise with WuXi’s anti-CD3 mAb, a TCE platform, and its proprietary bispecific antibody platform, WuXiBody™. Medigene wants to extend TCRs into new modalities, such as TCR-TCEs. The companies say the collaboration has the potential to become a multi-TCR program partnership. Wuxi Biologics is a Shanghai CRDMO focused on biologic drug development. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here